CRC patient tumors, which are initially oxaliplatin sensitive, display increased LAT3 mRNA levels compared to normal tissue, while many other tumor types tend to downregulate LAT3 compared to normal tissue (i.e. breast, lung, ovary, pancreas; Fig. 6A). This evidence concerns the gene SLC43A1 and colorectal carcinoma.